As screening with PSA became common, the percentage of prostate cancer cases that were metastatic at diagnosis declined from 25% in 1980 to 4% in 2002 (Etzioni, Gulati, Falcon, & Penson, 2008). This evidence concerns the gene KLK3 and prostate cancer.